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Introduction {#jdi12679-sec-0001}
============

The programmed death 1 (PD‐1) molecule that is expressed on activated T cells binds to the tumor‐expressed ligands, PD‐L1 and PD‐L2, resulting in downregulation of T‐cell activation and promotion of tumor immune escape[1](#jdi12679-bib-0001){ref-type="ref"}. The anti‐PD‐1 antibodies, pembrolizumab and nivolumab, represent an effective treatment option for metastatic melanoma, as well as for other cancer entities[1](#jdi12679-bib-0001){ref-type="ref"}. In contrast, these anti‐PD‐1 antibodies can activate autoreactive T cells and induce immune‐related adverse events[2](#jdi12679-bib-0002){ref-type="ref"}. Recently, there have been increasing reports of anti‐PD‐1 antibody‐induced diabetes that is similar to type 1 diabetes. The mode of onset of type 1 diabetes (acute, slow or fulminant) is strongly influenced by human leukocyte antigen (HLA) genes[3](#jdi12679-bib-0003){ref-type="ref"}, [4](#jdi12679-bib-0004){ref-type="ref"}, [5](#jdi12679-bib-0005){ref-type="ref"}. It has been considered that the HLA genotype might be involved in the onset of diabetes with anti‐PD‐1 therapy, because many such cases have a susceptible HLA genotype for type 1 diabetes[6](#jdi12679-bib-0006){ref-type="ref"}, [7](#jdi12679-bib-0007){ref-type="ref"}.

Case Report {#jdi12679-sec-0002}
===========

A 68‐year‐old Japanese man with a height of 166 cm and weight of 42 kg (body mass index 14.9 kg/m^2^) who was receiving nivolumab (3 mg/kg, once every 2 weeks) for chemoresistant adenosquamous carcinoma of the lung was referred to the Department of Endocrinology and Metabolism, Toranomon, Tokyo, Japan, for hyperglycemia. Six years previously, he was diagnosed with pancreatic diabetes after a pancreaticoduodenectomy for pancreatic cancer. Three years later, lung surgery and chemotherapies were carried out for right lower lobe primary lung cancer. One year after that, lung cancer recurred in both lobes. Despite three lines of chemotherapy with carboplatin/nab‐paclitaxel, docetaxel and pemetrexed, the cancer resulted in progressive disease. During this period, hemoglobin A1c levels shifted between 5.5 and 7.0% without medication for diabetes. The diabetes mellitus was considered to be caused by a combination of partial pancreatic resection and episodic steroid administration as an antiemetic. Nivolumab was selected as the fourth line of chemotherapy for advanced lung cancer. His blood glucose levels had been normal until the second course of nivolumab. The third course of nivolumab was given 30 days after nivolumab initiation. The patient visited our hospital 10 days after the third infusion of nivolumab because hyperglycemia was noted by the general practitioner. Laboratory data showed elevated blood glucose (330 mg/dL) and hemoglobin A1c (8.0%) levels, although ketosis and ketoacidosis were not detected. The serum C‐peptide level (3.16 ng/mL) indicated that the diabetic condition was not in an insulin‐dependent state. Intensive insulin therapy was started immediately. Because the three courses of nivolumab treatment had resulted in progressive disease of the lung cancer, we decided not to apply a fourth course.

The serum amylase, lipase and elastase levels were normal, and islet autoantibodies were negative (Table [1](#jdi12679-tbl-0001){ref-type="table-wrap"}). An abdominal computed tomography scan and magnetic resonance imaging showed no changes in the residual pancreas (data not shown). Urinary C‐peptide excretion was decreased to 12.7 μg/day at 3 days after his admission to our hospital (day 3), and the serum C‐peptide level had dropped to 0.39 ng/mL on day 15 (Figure [1](#jdi12679-fig-0001){ref-type="fig"}), showing decreased insulin secretion from the residual pancreas (Figure [1](#jdi12679-fig-0001){ref-type="fig"}). Total daily insulin requirement increased gradually, reaching over 50 Units/day. Amrubicin and 8 mg of dexamethasone were give as the fifth line of chemotherapies on days 21--23. At this period, the serum C‐peptide and the required total daily insulin amount were transiently increased because of the administration of dexamethasone (Figure [1](#jdi12679-fig-0001){ref-type="fig"}). A 1 mg glucagon load test on day 41 showed a decreased C‐peptide response, changing from 0.69 to 1.06 ng/mL, with a decreased delta C‐peptide response of 0.37 ng/mL (Table [2](#jdi12679-tbl-0002){ref-type="table-wrap"}). HLA genotype analysis showed that the patient had HLA A\*24:02 and DRB1\*09:01, both of which are strongly associated with type 1 diabetes (Table [3](#jdi12679-tbl-0003){ref-type="table-wrap"}). Simultaneously, the patient had the HLA genotype DRB1\*15:02, which is assumed to be protective against type 1 diabetes in the Japanese population[5](#jdi12679-bib-0005){ref-type="ref"}. He was discharged from our hospital and transferred to a hospice on day 47, and died from progression of the lung cancer on day 73.

###### 

Laboratory data on admission

  --------- ------------ ---------------------------- ----------------
  TP        8.7 g/dL     WBC                          13,900/μL
  Alb       3.0 g/dL     RBC                          428 × 10^6^/μL
  LDH       249 IU/L     Hb                           12.7 g/dL
  AST       19 IU/L      Plt                          419 × 10^3^/μL
  ALT       17 IU/L      TSH                          0.674 μIU/mL
  ALP       485 IU/L     Free thyroxine               1.56 ng/dL
  T‐Bil     0.6 mg/dL    GAD Ab                       \<5 U/mL
  γGTP      104 IU/L     IA‐2 Ab                      \<4 IU/L
  UA        4.3 mg/dL    Insulin antibody             \<0.4 IU/L
  Amylase   87 IU/L      Anti‐thyroid peroxidase Ab   11.0 IU/mL
  Lipase    83 IU/L      Anti‐thyroglobulin Ab        \<10.0 IU/mL
  HbA1c     8.0%         TSH receptor Ab              0.6 IU/L
  Na        128 mmol/L                                
  K         4.3 mmol/L   Venous blood pH              7.35
  Cl        90 mmol/L    Venous blood base excess     −0.2 mmol/L
  Ca        9.3 mg/dL    Venous blood HCO~3~ ^−^      25 mmol/L
  P         3.4 mg/dL                                 
  BUN       23 mg/dL     Urinary specific gravity     1.021
  Cr        0.93 mg/dL   Urinary pH                   5.5
  CRP       13 mg/dL     Urinary ketone               Negative
  --------- ------------ ---------------------------- ----------------

γGTP, γ‐glutamyltranspeptidase; Alb, albumin; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; CRP, C‐reactive protein; GAD, glutamic acid decarboxylase; IA‐2, insulinoma‐associated antigen‐2; Plt, platelet; RBC, red blood cell; T‐Bil, total bilirubin; TP, total protein; TSH, thyroid‐stimulating hormone; UA, uric acid.
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![Changes in total daily insulin (filled bar), fasting serum C‐peptide (●) and fasting blood glucose (○) over time. The patient was admitted to our hospital on day 0. The third course of nivolumab was given on day --10. Blood glucose level and serum C‐peptide on day 0 was measured under non‐fasting conditions. Intensive insulin therapy was started on day 0. Amrubicin and 8 mg of dexamethasone were given as the fifth line of chemotherapy on day 21--23.](JDI-9-438-g001){#jdi12679-fig-0001}

###### 

Plasma glucose and C‐peptide responses to the 1‐mg intravenous glucagon load test at 41 days after admission

  Time                           0 min   6 min
  ------------------------------ ------- -------
  Plasma glucose (mg/dL)         130     141
  C‐peptide reactivity (ng/mL)   0.69    1.06

C‐peptide and blood glucose levels at 6 min after 1 mg glucagon given intravenously.
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###### 

Clinical characteristics of the present case and previously reported cases of anti‐programmed cell death‐1‐induced diabetes

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case no Age (years)/sex   Target tumor             Anti‐PD‐1 Drug      Initial presentation HbA1c, BG    Onset time of diabetes   Auto‐ antibody   HLA                       Ref
  ------------------------- ------------------------ ------------------- --------------------------------- ------------------------ ---------------- ------------------------- -----------------------------------------
  No 1 68/M                 Lung Cancer              Nivolumab\          Hyperglycemia\                    5 weeks                  Negative         A24:02, DRB1\*09:01\      Present report
                                                     3 mg/kg, 2 weekly   8.0%, 330 mg/dL                                                             DRB1\*15:02               

  No 2\                     Malignant Melanoma       Nivolumab\          Ketouria\                         1 year                   Negative         DRB1\*04:05\              [6](#jdi12679-bib-0006){ref-type="ref"}
  55/F                                               2 mg/kg, 3 weekly   7%, 580 mg/dL                                                               DQB1\*04:01               

  No 3\                     Malignant\               Nivolumab           DKA\                              5 months                 Negative         A2.1 + , DR4 +            [6](#jdi12679-bib-0006){ref-type="ref"}
  55/F                      Melanoma                                     6.9%, 532 mg/dL                                                                                       

  No 4\                     Lung Cancer              Nivolumab           DKA\                              \<1 month                GAD Ab           A2.1 + , DR4 +            [6](#jdi12679-bib-0006){ref-type="ref"}
  83/F                                                                   7.7%, 350 mg/dL                                                                                       

  No 5\                     Renal cell Carcinoma     Nivolumab           8.2%, 247 mg/dL                   4 months                 GAD Ab\          A2.1 + , DR4 +            [6](#jdi12679-bib-0006){ref-type="ref"}
  63/M                                                                                                                              ICA, IA                                    

  No 6\                     Lung Cancer              Nivolumab           Type 2 diabetes mellitus → DKA\   1 week                   GAD Ab           A2.1 +                    [6](#jdi12679-bib-0006){ref-type="ref"}
  58/M                                                                   9.7%, 749 mg/dL                                                                                       

  No 7\                     Malignant\               Pembrolizmab        Ketouria\                         \<1 month                Negative         DR4 +                     [6](#jdi12679-bib-0006){ref-type="ref"}
  64/F                      Melanoma                                     7.4%, 580 mg/dL                                                                                       

  No 8\                     Malignant Melanoma       Pembrolizmab\       DKA\                              6 weeks                  GAD Ab           DRB1\*04\                 [6](#jdi12679-bib-0006){ref-type="ref"}
  54/F                                               2 mg/kg, 3 weekly   Not shown                                                                   DQB1\*03:02               

  No 9\                     Lung Cancer              Anti‐PDL1 Ab        DKA\                              15 weeks                 GAD Ab\          Not reported              [6](#jdi12679-bib-0006){ref-type="ref"}
  70/M                                                                   9.8%, 411 mg/dL                                            IA                                         

  No 10\                    Sarcomatoid SCC of jaw   Anti‐PDL1 Ab        DKA\                              7 weeks                  GAD Ab           DR3‐DQ2\                  [6](#jdi12679-bib-0006){ref-type="ref"}
  66/F                                                                   9.4%, 752 mg/dL                                                             DR4‐DR8                   

  No 11\                    Malignant Melanoma       Pembrolizmab        DKA\                              5 weeks                  Negative         Not reported              [6](#jdi12679-bib-0006){ref-type="ref"}
  44/F                                                                   6.8%, 908 mg/dL                                                                                       

  No 12\                    Malignant Melanoma       Nivolumab\          DKA\                              121 days                 Negative         DRB1\*11:01 13:02:01\     [7](#jdi12679-bib-0007){ref-type="ref"}
  66/F                                               2 mg/kg, 3 weekly   7.3%, 531 mg/dL                                                             DQB1\*03:01:01 06:04:01   

  No 13\                    Malignant Melanoma       Nivolumab\          DKA\                              15 weeks                 Negative         Not reported              [7](#jdi12679-bib-0007){ref-type="ref"}
  63/F                                               2 mg/kg, 3 weekly   8.9%, 661 mg/dL                                                                                       

  No 14\                    Lung Cancer              Pembrolizmab        Hyperglycemia                     1 month                  GAD Ab           Not reported              [7](#jdi12679-bib-0007){ref-type="ref"}
  76/M                                                                                                                                                                         

  No 15\                    Malignant Melanoma       Pembrolizmab\       Hyperglycemia\                    1 year                   GAD Ab           Not reported              [7](#jdi12679-bib-0007){ref-type="ref"}
  58/M                                               2 mg/kg, 3 weekly   9.7%, 408 mg/dL                                                                                       

  No 16\                    Hodgkin Lymphoma         Nivolumab\          Hyperglycemia\                    57 days                  Negative         HLA‐B\*40:02              [8](#jdi12679-bib-0008){ref-type="ref"}
  72/M                                               3 mg/kg, 2 weekly   8.0%, 290 mg/dL                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patient no 1 shows the present case. Onset time of diabetes is the time after administration of anti‐programmed cell death‐1 (PD‐1) antibody (Ab) to onset of hyperglycemia. BG, blood glucose; DKA, diabetic ketoacidosis; F, female; GAD, glutamic acid decarboxylase; IA, insulin antibody; ICA, islet cell antibody; M, male; PDL1, programmed death ligand 1; SCC, squamous cell carcinoma.
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Discussion {#jdi12679-sec-0003}
==========

The present report described a case of aggravation of pre‐existing diabetes, which was considered to be an additional effect of anti‐PD‐1 therapy on steroid diabetes and pancreatic diabetes as a result of partial pancreatectomy for pancreatic cancer. Most of the previously reported patients who developed diabetes after anti‐PD‐1 therapy showed a rapid decrease in insulin secretion and a fall into a complete insulin‐dependent state; this mode of onset of diabetes is similar to that of fulminant type 1 diabetes[6](#jdi12679-bib-0006){ref-type="ref"}, [7](#jdi12679-bib-0007){ref-type="ref"}, [8](#jdi12679-bib-0008){ref-type="ref"}. According to the Japan Diabetes Society, 12 out of 4,888 (0.25%) patients who had been given nivolumab developed type 1 diabetes[9](#jdi12679-bib-0009){ref-type="ref"}, [10](#jdi12679-bib-0010){ref-type="ref"}. The clinical characteristics of the present case and of 15 previously reported cases of diabetes associated with anti‐PD‐1 antibody are summarized in Table [3](#jdi12679-tbl-0003){ref-type="table-wrap"}. Islet autoantibodies were negative in the present case. Half of the previously reported patients who developed anti‐PD‐1 therapy‐induced diabetes likewise showed no detectable islet cell autoantibodies (Table [3](#jdi12679-tbl-0003){ref-type="table-wrap"}).

In contrast, the present patient did not show ketosis/ketoacidosis or complete depletion of insulin secretion, and these findings differ from those of many of the previously reported cases. The present patient required the large amount of insulin, presumably because of the enhanced insulin resistance induced by steroid administration during chemotherapy, and the extension of the tumor.

Most of the other cases reported to date had high‐risk HLA genotypes, such as DR4, for type 1 diabetes. In contrast, HLA analysis showed that the present patient had HLA‐DRB1\*15:02, which is dominantly protective HLA for type 1 diabetes, in addition to HLA‐DRB1\*09:01 and ‐A24:02, which are susceptible genotypes in the Japanese population[4](#jdi12679-bib-0004){ref-type="ref"}, [5](#jdi12679-bib-0005){ref-type="ref"}. This is the first case of hyperglycemia after anti‐PD‐1 therapy in a patient who has the HLA DRB1\*15:02 genotype that is resistant to type 1 diabetes. The difference in the HLA genotype between the present patient and previously reported cases might be one of the reasons why the present patient did not reach complete depletion of insulin secretion. The occurrence and progression of anti‐PD‐1 inhibitor‐induced diabetes might be influenced by multiple factors, such as background diabetic status and other underlying medical conditions, in particular, HLA genotypes. Although the relationship between anti‐PD‐1 antibody therapy‐induced diabetes and HLA genotypes is unclear, the protective HLA (HLA‐DRB1\*15:02) might exert a dominant negative effect against the progression of diabetes induced by anti‐PD‐1 antibody therapy.
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